Effect of Omega 3 Fatty Acids on Heart and Liver in Beta Thalassemia Patients

Sex: All

Ages: 6 Years – 18 Years

Healthy volunteers: No

Phase: PHASE2

Enrollment: 100

Sponsor: Ain Shams University

Summary

the aim of this interventional study to show the effect of taking omega 3 for about 6 months for patients beta thalassemia major maintained on standard of care and receiving the iron chelator deferasirox on liver, cardiac functions and transfusion index the patients randomly distributed to two groups group A receiving the omega 3 in dose 1gram pr day(50 patients) group b not receiving the drug

Eligibility Criteria

Inclusion Criteria: age: 6-18 years old children and adolescents with transfusion dependent thalassemia(TDT).diagnosis of TDT is based on clinical severity and transfsion requirements according to thalassemia international federation(TIF)guidelines Exclusion Criteria: * patients with infection or other inflammatory conditions patient with active hepatitis(serum transaminases\>3 times above upper limit of normal) participation in previous clinical trial or supplementation with antioxidants or vitamins with three months prior to study

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07863791). StuddyBuddy aggregates publicly available trial information.